Postoperative pain and morbidity at the donor site after palatal soft tissue harvesting: a systematic review Authors: Wee Jian Chong, Masfueh Razali, Badiah Baharin, Nik Madihah Nik Azis Published: 2025 ABSTRACT AbstractAimThis systematic review aims to evaluate the nature of postoperative pain and donor site morbidity following palatal soft tissue harvesting procedures, utilizing various wound dressings at the donor site.Materials and methodsA comprehensive search of five electronic databases and the grey literature was conducted of studies to June 2025, examining postoperative pain and morbidity following palatal graft harvesting. Eligible studies reported pain outcomes using Visual Analogue Scale (VAS) scores and assessed additional morbidity parameters. Risk of bias in randomized studies was assessed using the RoB 2.0 tool. Data on VAS scores were extracted for baseline and postoperative days 1, 3, 5, and 7. Donor site complications and morbidities were analyzed across various wound management approaches.ResultsSixty-eight studies met the inclusion criteria, of which thirty-eight reported self-reported pain scores using the VAS, presented as mean and standard deviation. Patient-reported outcomes, including quality of life assessments, were commonly used to evaluate broader postoperative impacts. Additional morbidities reported included bleeding, burning sensations, altered sensory perception, and changes in feeding behavior.ConclusionsPostoperative pain is most pronounced within the first three days following surgery, with progressive reduction over time. The application of wound dressings or physical barriers can effectively reduce pain, although outcomes vary depending on the type of intervention used. Other commonly reported complications include bleeding, burning sensations, altered sensation, and changes in feeding behavior.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12903-025-07198-2.Keywords: Gingival graft, Palatal wound dressing, Pain, Postoperative morbidities Background Palatal soft tissue harvesting procedures, such as free gingival grafts (FGG) and de-epithelialized connective tissue grafts (DGG), have become increasingly common in periodontal and implant therapy due to rising aesthetic demands and the need for optimal soft tissue management [1]. These techniques involve the surgical removal of epithelialised or subepithelial connective tissue from the palate for use in recipient sites elsewhere in the oral cavity. While the initial focus was on preserving or creating a band of attached keratinised tissue, modern approaches now aim to promote periodontal health by preventing further tissue loss, restoring lost hard and soft tissues, and improving esthetic outcomes [2]. The palate is the most commonly used donor site for autogenous soft tissue grafts in periodontal and implant procedures [3]. However, harvesting tissue for procedures such as FGG or DGG results in an open wound at the donor site, which typically requires up to four weeks for complete healing. Consequently, these procedures are frequently associated with postoperative morbidity, particularly pain and discomfort at the palatal site. Wessel et al. [4] reported a mean Visual Analogue Scale (VAS) pain score of 4.8 during the first three postoperative days, with 90 percent of participants experiencing pain. Wounds left to heal by second intention are particularly prone to delayed healing and increased patient morbidity. This is primarily due to the absence of complete wound edge approximation, which hinders re-epithelialization and tissue closure, thereby prolonging the inflammatory phase of healing. As a result, considerable attention has been directed toward interventions aimed at improving wound healing and minimising postoperative discomfort at the donor site. These include the use of medicinal plant extracts, topical agents, haemostatic products, wound dressings, and protective stents [5]. More recently, biologically active materials such as platelet concentrates have shown promising results, particularly in accelerating the initial phases of wound healing and reducing inflammation and pain. Despite the utility of these dressing materials, Zucchelli et al. reported that 28% of patients undergoing gingival graft harvest experienced dehiscence or necrosis of the primary palatal flap during the first seven days of healing [6]. Other reported complications include excessive haemorrhage, postoperative bone exposure, recurrent herpetic lesions [7], and most frequently, postoperative pain. Previous systematic reviews have examined donor site morbidity following palatal soft tissue harvesting, yet their conclusions differ, and methodological limitations remain. Oliveira et al. [8], in a network meta-analysis, concluded that leukocyte and platelet-rich fibrin (L-PRF) was the most effective intervention for reducing postoperative pain, accelerating wound healing, and minimising complications. In contrast, Leite et al. [5] reviewed 54 studies encompassing 43 different interventions and found that collagen hemostatic sponges, platelet-rich fibrin, and photobiomodulation were among the most frequently reported. However, they noted significant challenges in comparing the effectiveness of interventions due to heterogeneity in study designs, outcome measures, and combined therapies. While improvements in postoperative pain and oral health–related quality of life were generally observed, the lack of standardised tools and the diversity in methodologies limited the strength of comparisons. Given the discrepancies in the findings and the ongoing emergence of new evidence, the present systematic review aims to provide an updated and comprehensive synthesis of clinical studies involving human patients undergoing palatal soft tissue harvesting procedures, with a focus on evaluating the postoperative pain and other morbidities at the donor site in relationship to the various wound dressings. Methodology Protocol development and focused question This review's protocol was established a priori and registered in PROSPERO (CRD) on 24th January 2024 with all post hoc changes reported (see Appendix 1). The conduct and reporting of this review are guided by the Cochrane Handbook and the PRISMA statement [9], respectively. The two focused questions this review aims to answer are as follows: a) "What is the postoperative pain score after palatal soft tissue harvesting procedures using different wound dressings at the donor site?" and b) "What other postoperative morbidities are experienced by patients undergoing palatal soft tissue harvesting procedures?". Eligibility criteria All studies that included palatal graft harvesting were searched to conduct a systematic review. The focused question was constructed using the PVO acronym (Population, Variable and Outcome) and study design as follows: Population: Patients undergoing palatal soft tissue harvesting. Population: Patients undergoing palatal soft tissue harvesting. Variable: The utilisation of different palatal wound dressings at the donor site. No restriction was applied to the type and definition of the wound dressing. Variable: The utilisation of different palatal wound dressings at the donor site. No restriction was applied to the type and definition of the wound dressing. Outcomes: i) Postoperative pain evaluated at the donor site by the patient. No restrictions were applied to the method of evaluation of pain (e.g. VAS score, pain indexes, postoperative analgesic intake); ii) Postoperative morbidities evaluated at the donor site by the patient. Outcomes: i) Postoperative pain evaluated at the donor site by the patient. No restrictions were applied to the method of evaluation of pain (e.g. VAS score, pain indexes, postoperative analgesic intake); ii) Postoperative morbidities evaluated at the donor site by the patient. Study design: Only controlled clinical trials and randomized clinical trials were included. Studies were excluded if they were animal studies, in vitro studies, observational studies, case reports, case series, systematic reviews, meta-analyses, and narrative studies. Study design: Only controlled clinical trials and randomized clinical trials were included. Studies were excluded if they were animal studies, in vitro studies, observational studies, case reports, case series, systematic reviews, meta-analyses, and narrative studies. The search was limited to articles in the English language and limited to publications up to June 2025. Information sources and search An electronic search of the literature published up to June 2025 was performed using five online databases: MEDLINE (through PubMed), Scopus, Web of Science, Cochrane Library and Embase. The following search terms were used: (“ Postoperative” OR “ Recovery”) AND (“Morbidities” OR “pain” OR discomfort” OR “bleeding” OR” Visual analogue scale” OR” Numerical rating scale” OR “ patient outcome”) AND (“Palatal” OR “palate” OR “ donor site” AND “soft tissue harvesting” OR “de-epithelialized gingival graft” OR “subepithelial connective tissue graft” OR” connective tissue graft” OR”Free gingival graft” OR “periodontal surgery” OR”mucogingival surgery” OR”palatal graft” OR “gingival graft”). Unique and specific search strings were formulated for each database, using the key concepts in different combinations (Appendix 1). Additional records were identified through a manual search of the reference lists. Study selection and data extraction Records were first screened at the title and abstract level. Extraction and synthesis of information from the included studies were summarized into a table of evidence by the first reviewer (CWJ) and second reviewer (NMNA) separately to ensure that they were aligned with the research questions. Any disagreement was resolved by a third author (BB). The online literature review application, Rayyan software (http://rayyan.ai/ accessed on 1 August 2025) was used for screening of the records. Subsequently, a full-text evaluation was independently conducted by two reviewers. Study characteristics and main findings were collected, analysed, and then summarised in tables for qualitative and quantitative analyses. Extracted data from the included studies included publication details (first author, year of publication, and country of study), study design (limited to clinical trials), study objectives, population and sample size, postoperative assessment tools and methods used at the palatal donor sites, assessments of postoperative morbidities at the donor site, types of treatments at the donor site post-surgery, and authors' conclusions. Risk of bias assessment Once the full-text article analysis was completed, two reviewers (CWJ, NMNA) conducted the risk of bias evaluation according to Cochrane guidelines using the risk of bias 2.0 tool [10]. All risk of bias assessments were performed using the pain score as the outcome. Data synthesis and analysis Standardised, pre-piloted forms were designed for data extraction and collection. All outcome variables for the PVO questions were recorded at Days 1, 3, 5, and 7 post-intervention. If the authors presented data at different time intervals, the information was not recorded. When data were absent, authors were contacted, and their responses were documented. If necessary and possible, outcome variables were calculated by the reviewers based on the data available in the individual selected studies. The heterogeneity was assessed using the I2 index, respectively; the latter was defined as the percentage of variation in the global estimate that was attributable to heterogeneity (I2 = 25%: low; I2 = 50%: moderate; I2 = 75%: high heterogeneity). Statistical significance was set at p ≤ 0.05. Results Study selection and characteristics Overall, the search strategy generated 307 records from five databases. 118 duplicates were excluded, and 189 records were assessed based on their titles and abstracts. A further 7 records were removed based on the title. Of these, 182 underwent full-text evaluations. 123 articles were excluded due to incorrect study method/outcome, type of articles that were journal articles, review papers, narrative reviews, case series, book chapters, systematic reviews, and meta-analyses. A manual search was done and a total of 12 articles were identified. Two articles were excluded due to the wrong outcome. Finally, a total of sixty-nine articles were included in the final analysis. The PRISMA flow chart for the study selection is reported in Fig. 1, depicting the number of included studies at each step of the screening process. PRISMA flow chart of the number of studies included at each step of the screening process Characteristics of included studies A total of 69 studies were included, as outlined in Table 1. All articles were published in English and represented a wide geographical distribution, spanning fourteen countries. The majority of studies were conducted in Turkey (n = 18), followed by Iran (n = 10), Brazil (n = 9), Egypt (n = 8), India (n = 6), Italy (n = 6), the United States (n = 4), Saudi Arabia (n = 3), and one study each from Jordan, Portugal, Spain, Syria, and Thailand. All studies employed either the free gingival graft (FGG) or de-epithelialized gingival graft (DGG) technique, with the palatal donor site healing by secondary intention. Except for one quasi-randomised controlled clinical trial by Oliveira et al. [8], all included studies were randomized controlled trials. Ten of these employed a split-mouth design, namely those by Bitencourt et al. [20], Doshi et al. [24], Heidari et al. [35], Karimi et al. [41], Lafzi et al. [45], Morshedzadeh et al. [50], Patarapongsanti et al. [56], Samani et al. [59], Tabari et al. [68], and Yaghobee et al. [76]. Collectively, the studies involved a total of 2,447 participants. Table 1Characteristics of the included studiesAuthor (Year of publication)CountryStudy DesignSample size (Male: Female)Length of follow-up (Days)InterventionsAl-Hezaimi (2011) [11]Saudi ArabiaRCT68 (31:37)2Ketorolac Tromethamine (KT) Adhesive Film, n = 34Adhesive Film Without KT, n = 34Suture, n = 12Al-Sherbini et al. (2024) [12]EgyptRCT2028Ozone Therapy, n = 10Periodontal Dressing, n = 10Alasfar et al. (2023) [13]SyriaRCT22 (6:16)60Periodontal Dressing (Non-Eugenol Pack, Coe-Pak TM), n = 1110% Curcuma Longa Extract Gel (Turmeric Gel), n = 11Alasqah et al. (2022) [14]Saudi ArabiaRCT20 (10:10)28Honey-Based Dressing Material, n = 10No Dressing, n = 10Alghriany et al. (2024) [15]EgyptRCT18 (7:11)30Orange Peel Polymethoxy-Flavonoids (OPMF), n = 6Alveogyl, n = 6Placebo Dough Material, n = 6Alkaya et al. (2023) [16]TurkeyRCT60 (29:31)56Gelatin-Based Hemostatic Agent + Suture, n = 28Zinc-Containing Surgical Stent, n = 24Alpan and Cin (2021) [17]TurkeyRCT60 (24:34)28No Treatment, n = 15HA Gel (600 Mg/100 G High Molecular Weight Hyaluronic Acid, n = 15HOCl Spray (170–200 Ppm, Ph7.1), n = 15Furbiprofen Spray (0.075gr Furbiprofen), n = 15Bahammam (2018) [18]Saudi ArabiaRCT24 (14:10)32Suture, n = 12PRF + Suture, n = 12Basma et al. (2023) [19]USARCT72 (27:45)14Collagen Plug + Sutures, n = 18Collagen Plug With Cyano-Acrylate, n = 18PRF + Sutures, n = 18Stent, n = 18Bitencourt et al. (2022) [20]BrazilRCT (Split Mouth)44 (11,33)21Diode Laser (808 nm, 50/60, 100 Mw, 3 J), n = 22Placebo, n = 22Castro-Gaspar et al. (2021) [21]SpainRCT24 (12:12)60Suture Group, n = 12Cyanoacrylate Adhesive, n = 12da Silva Neves et al. (2016) [22]BrazilRCT51 (23:28)90Suture, n = 18PBM 60, n = 18PBM 30, n = 18Dharani et al. (2025) [23]IndiaRCT10 (1:9)28Ozonated Oil + Stent, n = 5Stent Only,n = 5Dias et al. (2015) [24]BrazilRCT32 (15:17)90LLLT SHAM, n = 16LLLT, n = 16Doshi et al. (2021) [25]USARCT (Split mouth)20 (16:4)21Placebo + Stent, n = 10Topical Phenytoin + Stent, n = 10Ehab et al. (2020) [26]EgyptRCT36 (12:24)35Gelatin Sponge, n = 18Alvogyl, n = 18Eldien et al. (2022) [27]EgyptRCT3960Platelet Rich Fibrin Membrane, Suture, Palatal Stent, n = 13Ozonated Olive Oil, Palatal Soft Stent, n = 13Periodontal Pack, Palatal Soft Stent, n = 13Eltas et al. (2014) [28]TurkeyRCT48 (24:24)14Periodontal Dressing, n = 12Essix Retainer, n = 12Modified Essix Retainer, n = 12Modified Hawley, n = 12Eltayeb et al., (2021) [29]EgyptRCT24 (9:15)270Laser-Harvested Gingival Graft, n = 8Blade-Harvested Gingival Graft With Acrylic Palatal Stent, n = 8*Without Laser Modifications At Recipient SiteBlade-Harvested Gingival Graft With Acrylic Palatal Stent, n = 8*With Laser Modifications At Recipient SiteFemminella et al. (2016) [30]ItalyRCT40 (15:25)30Gelatin Sponge + Suture,n = 20PRF + Suture, n = 20Garapati et al. (2023) [31]IndiaRCT60 (38:22)42Blue®M Gel + Absorbable Gelatin Sponge, n = 30Absorbable Gelatin Sponge, n = 30Gatti et al. (2023) [32]ItalyRCT42 (21:21)NAOxidized Regenerated Cellulose + Suture, n = 21L-PRF + Suture,n = 21Gulsever et al. (2025) [33]TurkeyRCY26 (13:13)42leukocyte- and platelet-rich fibrin (L-PRF) membrane + suture, n = 13Sutures only, n = 13Hassan et al. (2021) [34]EgyptRCT3942MEBO + Periodontal Pack, n = 130.2% Hyaluronic Acid Gel + Periodontal Pack, n = 13Periodontal Pack Only, n = 13Heidari et al. (2017) [35]IranRCT (Split mouth)12 (4:8)45Diode Laser, n = 12Laser Sham, n = 12Işler et al. (2018) [36]TurkeyRCT48 (21:27)56Placebo, n = 12Flurbiprofen Group, n = 12*using SCTG techniquePlacebo, n = 12Flurbiprofen Group, n = 12*using FGG techniqueIşler et al. (2018a) [37]TurkeyRCT36 (12:24)30No Treatment, n = 12Laser Group, n = 12Ozone Group, n = 12Işler et al. (2019) [38]TurkeyRCT60 (16:44)14Suture, n = 10PRF + Suture, n = 10Essix Retainer + Suture, n = 10Ozone + Suture, n = 10LLLT + Suture, n = 10Collagen Sponge + Suture, n = 10Juber et al. (2023) [39]BrazilRCT28 (14:14)14Ozonated Sunflower Oil, n = 14Non-Ozonated Sunflower Oil, n = 14Kadkhoda et al. (2020) [40]IranRCT27 (14:13)21Suture, n = 12Human Amniotic Membrane Dressing + Suture, n = 15Karimi et al. (2024) [41]IranRCT (split mouth)15 (8:7)90Cyanoacrylate, n = 15Suture Only, n = 15Keceli et al. (2015) [42]TurkeyRCT33 (5:28)28Stent, n = 16Medicinal Plant Extract + Stent, n = 17Khalil et al. (2022) [43]JordonRCT21 (6:15)180Collagen Sponge + HA + Periodontal Dressing, n = 11Collagen Sponge + Periodontal Dressing, n = 10Kızıltoprak and Uslu (2020) [44]TurkeyRCT36 (9:27)90Coe Pack, n = 12AFG + Coe Pack, n = 12I-PRF + Coe Pack, n = 12Lafzi et al. (2019) [45]IranRCT (Split Mouth)12 (6:6)30Diode laser (808 nm, 50mW, 15 J/cm2, 30 s), n = 6Spontaneous Healing, n = 6Madi and Kassem (2018) [46]EgyptRCT4014Petroleum Gel, n = 10Simvastatin Suspension,n = 10Simvastatin/Chitosan Gel, n = 10Chitosan Gel, n = 10Meza-Mauricio et al. (2023) [47]BrazilRCT32 (8:24)14Collagen Sponge + Suture,n = 16Collagen Sponge Coated With A Flowable Resin Composite, n = 16Miguel et al., (2020) [48]BrazilRCT53 (19:34)90Suture + Electrotherapy Treatment (100 Μa, 9 kHz, 120 Sec, n = 26Suture + Placebo, n = 27Miguel et al. (2021) [49]BrazilRCT44 (17:27)90Emdogain, n = 22Spontaneous Healing, n = 22Morshedzadeh et al. (2022) [50]IranRCT (Split mouth)14 (10:4)60Sham Irradiation + Stent, n = 8LLLT Gaalas 940 Nm, 5 J/Cm + Stent, n = 8Nabiyi et al. (2024) [51]IranRCT39 (6:33)42Mucoadhesives Containing 0.8% HA, n = 13Mucoadhesives Containing 0.2%, n = 13Mucoadhesives Only, n = 13Oliveira et al., (2023) [52]BrazilQuasi-randomised controlled clinical trial42 (11:31)28Placebo Gel, n = 14Green Tea Extract And HA Gel, n = 14Sutures Only, n = 14Ozcan et al. (2017) [53]TurkeyRCT12542L-PRF (2700 Rpm For 12 Min) + Cyanoacrylate Adhesive, n = 42Cyanoacrylate Adhesive, n = 42Palatal Stent, n = 41Ozcelik et al. (2016) [54]TurkeyRCT52180Low-Intensity Laser Therapy, n = 26Collagen Sponge + Suture, n = 26Palombo et al. (2024) [55]ItalyRCT32 (16:16)21Compressive Suture + Hemostatic Sponge, n = 16Sutureless Approach, n = 16Patarapongsanti et al. (2019) [56]ThailandRCT (Split mouth)18 (7:11)28Oxidised Regenerated Cellulose, n = 9PRF + suture, n = 9Pekbağrıyanık et al. (2021) [57]TurkeyRCT36 (5:31)56Stent, n = 18Non-thermal atmospheric pressure plasma + Stent, n = 18Rossmann et al. (1999) [58]USARCT2921Gelatin Sponge, n = 9Oxidised Regenerated Cellulose, n = 9Gauze, n = 8Samani et al. (2017) [59]IranRCT (Split mouth)1014PRP (400 Rpm For 8 Min), n = 10Spontaneous Healing, n = 10Sankar et al. (2021) [60]IndiaRCT20 (15:5)21Chitosan + Stent, n = 10Aloe Vera + Chitosan + Stent, n = 10Scott et al. (2024) [61]USARCT74 (23:51)30Oxidised Cellulose Haemostatic Agent, n = 37Platelet Rich Fibrin, n = 37Sen et al. (2024) [62]TurkeyRCT39 (3:36)180L-PRF, n = 13A-PRF, n = 13Collagen Sponhe, n = 13Shanmugam et al., (2010) [63]IndiaRCT3242Collagen Sponge, n = 16Coe-Pak, n = 16Sharma et al. (2019) [64]IndiaRCT20 (5:15)31Collagen Dressing, n = 10Autogenous PRF Membrane, n = 10Soheilifar et al. (2015) [65]IranRCT26 (9:17)14Coe-Pak, n = 13Placebo, n = 13Sousa et al. (2020) [66]PortugalRCT25 (9:16)90Gelatin Sponge + Suture, n = 11A-PRF Clot Membranes + Suture, n = 14Spin et al. (2021) [67]BrazilRCT24 (6:18)30Latex Membrane + Acrylic Plate And Surgical Cement, n = 10Acrylic Plate And Surgical Cement, n = 14Polytetrafluoroethylene Sutures, n = 18Tabari et al. (2023) [68]IranRCT (Split mouth)2042Modified Hawley Retainer, n = 10Modified Hawley Retainer With 5% Propolis Oral Ointment, n = 10Tasdemir et al. (2016) [69]TurkeyRCT30 (7:23)13Stent, n = 15Ozone Therapy + Stent, n = 15Tavelli et al. (2018) [70]ItalyRCT50 (17:33)14Cyanoacrylate Adhesive + Suture, n = 10Spongostan + Suture, n = 10Periodontal Dressing, n = 10Spongostan + Cyanoacrylate + Suture, n = 10Suture, n = 10Tavelli et al. (2019) [71]ItalyRCT44 (15:29)14Collagen Sponge + Suture, n = 22Cyanoacrylate + Collagen Sponge + Suture, n = 22Tirone et al. (2021) [72]ItalyRCT50 (18:32)56Collagen Sheet + Suture, n = 25Bipolar Coagulator + Collagen Sheet + Suture, n = 25Ustaoğlu et al. (2016) [73]TurkeyRCT34180Non-Eugenol Pack + Acrylic Stent, n = 18T-PRF + Non-Eugenol Pack + Acrylic Stent, n = 16Ustaoğlu et al. (2017) [74]TurkeyRCT35 (4:31)28Laser (Gaalas, 940 Nm, 3 W, 8.6 J/Cm2, 8 Sec) + Acrylic Stent, n = 17Acrylic Palatal Stent, n = 18Yadav et al. (2024) [75]IndiaRCT32 (16:16)28No Treatment, n = 16Chitosan-Based Dressing + Suture, n = 16Yaghobee et al. (2018) [76]IranRCT (split mouth)12 (3:9)28Erythropoitin Gel, n = 6Gel Alone, n = 16Yıldırım et al. (2017) [77]TurkeyRCT36 (9:27)42Periodontal Dressing, n = 120.12% HA + Periodontal Dressing, n = 120.8% HA + Periodontal Dressing, n = 12Yılmaz et al. (2022) [78]TurkeyRCT27 (22:5)180No Treatment, n = 13Cyanoacrylate, n = 14Yussif et al. (2021) [79]EgyptRCT24 (11:13)30Propylene Mesh, n = 12Acrylic Stent, n = 12NA Not available, PRF Platelet rich fibrin, NRS Numerical Rating Scale, VRS Verbal Rating Scale, PBM Photobiomodulation, CTG Connective tissue graft, LLLT Low-level laser therapy, SCTG Subepithelial connective tissue graft, FGG Free gingival graft, T-PRF Titanium-prepared platelet-rich fibrin, HA Hyaluronic acid, AFG Autologous fibrin glue, i-PRF Injectable platelet-rich fibrin, DGG Deepitheliazed gingival graft, OT Ozone therapy, A-PRF Advanced platelet-rich fibrin, PHT Phenytoin formulation, HOCI Hypochlorous acid, MEBO Moist exposed burn ointment, EPO Erythropoietin, n-Emo nano-emodin, PDT Photodynamic therapy, NSAID Non-steroidal anti-inflammatory drug, L-PRF Leucocyte- and platelet-rich fibrin, NAPP Non-thermal atmospheric pressure plasma Characteristics of the included studies Blade-Harvested Gingival Graft With Acrylic Palatal Stent, n = 8 *Without Laser Modifications At Recipient Site Blade-Harvested Gingival Graft With Acrylic Palatal Stent, n = 8 *With Laser Modifications At Recipient Site Placebo, n = 12 Flurbiprofen Group, n = 12 *using SCTG technique Placebo, n = 12 Flurbiprofen Group, n = 12 *using FGG technique NA Not available, PRF Platelet rich fibrin, NRS Numerical Rating Scale, VRS Verbal Rating Scale, PBM Photobiomodulation, CTG Connective tissue graft, LLLT Low-level laser therapy, SCTG Subepithelial connective tissue graft, FGG Free gingival graft, T-PRF Titanium-prepared platelet-rich fibrin, HA Hyaluronic acid, AFG Autologous fibrin glue, i-PRF Injectable platelet-rich fibrin, DGG Deepitheliazed gingival graft, OT Ozone therapy, A-PRF Advanced platelet-rich fibrin, PHT Phenytoin formulation, HOCI Hypochlorous acid, MEBO Moist exposed burn ointment, EPO Erythropoietin, n-Emo nano-emodin, PDT Photodynamic therapy, NSAID Non-steroidal anti-inflammatory drug, L-PRF Leucocyte- and platelet-rich fibrin, NAPP Non-thermal atmospheric pressure plasma Among the included studies, Işler et al. featured the most extensive design, incorporating one control group and five test groups [38]. The remaining studies included between one and four groups. All studies adopted a longitudinal design, although the duration of follow-up varied significantly. The longest follow-up was reported by Eltayeb et al. [29], extending up to 270 days (9 months). In contrast, Al-Hezaimi et al. [11] assessed outcomes only up to 48 h postoperatively, while Taşdemir et al. [69] followed participants for just 13 days. Gatti et al. [32], however, did not specify the duration of their follow-up. Risk of bias Quality assessment was independently conducted by two reviewers, based on the RoB 2.0 tool, as all included studies were randomised controlled trials. Study designs were accepted as reported unless contradictory evidence was identified. The quality assessment results are depicted in Fig. 2. Among the 69 included studies, the majority were assessed as having a high risk of bias or raising some concern, while only 12 studies were deemed to have a low risk of bias. Among the RoB 2.0 domains, Domain 5 (selection of the reported result) had the lowest risk, while Domain 4 (measurement of the outcome) contributed most to the overall bias concerns. Risk of bias using the RoB 2.0 tool for randomised controlled trial studies Between-study heterogeneity On Day 7, three forest plots were generated to visually demonstrate the variability in postoperative pain outcomes across different intervention types: physical barriers [21, 28, 38, 41, 63, 78], laser therapy/photobiomodulation/ozone [12, 24, 38, 54], and platelet-rich fibrin (PRF) [30, 33, 38, 59, 62, 64], all measured using the Visual Analogue Scale (VAS). Day 7 was selected as it was the most consistently reported time point across the included studies. The weighted mean pain scores at Day 7 showed that PRF-treated sites reported the lowest pain levels (mean 16.729, 95% CI: 4.402 to 29.056), followed by laser/photobiomodulation/ozone (mean 17.636, 95% CI: −5.646 to 40.918), and physical barriers (mean 28.119, 95% CI: 7.003 to 49.205). However, the 95% confidence intervals were wide and overlapping across interventions, with some crossing zero, reflecting inconsistency in both the direction and magnitude of the reported effects. The I2 statistics for all three intervention categories indicated substantial to considerable heterogeneity: physical barriers (I2 = 95%), laser therapy/photobiomodulation/ozone (I2 = 94%), and PRF (I2 = 94%). These findings highlight marked variability among the included studies, likely attributable to differences in study designs, intervention protocols, and outcome assessments. As a result, proceeding with meta-analysis to draw more meaningful conclusions was not feasible. Pain indexes and other measures of pain Pain perception is the most reported method used for post-palatal soft tissue harvesting evaluation at the donor site (Table 2). The VAS using the 10-cm (100-mm) was the most used tool for assessing pain intensity at the donor site. Out of the 69 included articles, 39 reported postoperative pain using the VAS tool. Other pain scales, such as the 101-point Numerical Rating Scale (NRS-101) and the three or four-point Verbal Rating Scale (VRS), were also employed to assess postoperative morbidities. Meza-Mauricio et al., [47] utilized the NRS tool to report postoperative pain, while Bahammam et al., [18] employed both NRS-101 and VRS-4 in addition to VAS to measure patients' postoperative pain in their study. In contrast, Castro-Gaspar et al., [21] used the VRS to evaluate the degree of inflammation. Additionally, the amount of postoperative analgesic consumption was recorded as an objective measure of pain management. Table 2Pain reported in visual analogue scale (VAS) on Days 1, 3, 5 and 7 post-intervention at the palatal graft harvesting siteAuthor, Year of publicationInterventionsVAS on Day 1VAS on Day 3VAS on Day 5VAS on Day 7Al-Hezaimi (2011) [11]Ketorolac tromethamine (KT) adhesive film, n = 347.3 ± 5.2NANANAAdhesive film without KT, n = 348.5 ± 7.6NANANASherbine et al. (2024)Ozone therapy, n = 10NA11.0 ± 12.0NA8.0 ± 9.0Periodontal dressing, n = 10NA34.0 ± 28.0NA32.0 ± 26.0Alkaya et al. (2023) [16]Gelatin-based hemostatic agent + suture, n = 2851 ± 2535 ± 24NA22 ± 17Zinc-containing surgical stent, n = 2451 ± 2512 ± 15NA4 ± 8Alghriany et al. (2024) [15]Orange peel polymethoxy-flavonoids (OPMF), n = 6NANANA3.83 ± 0.75Alveogyl, n = 6NANANA4.33 ± 1.21Placebo dough material, n = 6NANANA5.5 ± 1.64Castro-Gaspar et al. (2021) [21]Suture group, n = 12NA21.4 ± 19.9NA12.9 ± 13.3Cyanoacrylate adhesive, n = 12NA19 ± 19.7NA11 ± 24.7Dharani et al. (2025)Ozonated oil + stent, n = 5NANA50 ± 044 ± 5.48Stent only, n = 5NANA82 ± 8.366 ± 1.34Dias et al. (2015) [24]LLLT SHAM, n = 16NANANA4.6 ± 1.5LLLT, n = 16NANANA4.8 ± 1.7Doshi et al. (2021) [25]Placebo, n = 1019.0 ± 18.3NA15.8 ± 18.7NATopical phenytoin, n = 1014.5 ± 18.2NA14.2 ± 18.4NAEldien et al. (2022) [27]Platelet Rich Fibrin membrane, suture, palatal stent, n = 1322.0 ± 13.0NANA20.0 ± 14.1Ozonated olive oil, palatal soft stent, n = 1376.0 ± 5.4NANA40.0 ± 7.1Periodontal pack, palatal soft stent, n = 1390.0 ± 7.1NANA68.0 ± 8.4Eltas et al. (2014) [28]Periodontal dressing, n = 12NANANA67 ± 19Essix retainer, n = 12NANANA41 ± 13Modified Essix retainer, n = 12NANANA44 ± 16Modified Hawley, n = 12NANANA45 ± 13Femminella et al. (2016) [30]Gelatin sponge + suture,n = 20NANANA46 ± 2PRF + suture, n = 20NANANA24 ± 2Garapati et al. (2023) [31]Blue®m gel + Absorbable gelatin sponge, n = 30NANANA15.0 ± 7.7Absorbable gelatin sponge, n = 30NANANA24.7 ± 12.7Gulsever et al. (2025) [33]leukocyte- and platelet-rich fibrin (L-PRF) membrane + suture, n = 18.5 ± 11.4NANA2.3 ± 4.4Sutures only, n = 1346.9 ± 11.8NANA26.2 ± 12.6Işler et al. (2019) [38]Suture, n = 1022 ± 343 ± 539 ± 3119 ± 20PRF + suture, n = 107 ± 1503 ± 074 ± 1Essix retainer + suture, n = 109 ± 20011 ± 216 ± 16Ozone + suture, n = 109 ± 179 ± 1240 ± 286 ± 11LLLT + suture, n = 1019 ± 2711 ± 1915 ± 266 ± 16Collagen sponge + suture,n = 1013 ± 277 ± 1528 ± 3816 ± 22Kadkhoda et al. (2020) [40]Suture, n = 1273.3 ± 26.758.3 ± 23.542.5 ± 25.318.3 ± 25.5Human amniotic membrane dressing + suture, n = 1567.3 ± 29.440.0 ± 23.030.7 ± 22.520.0 ± 23.9Karimi et al. (2024) [41]Cyanoacrylate., n = 15NANANA75.2 ± 12.5Suture only, n = 15NANANA62.9 ± 12.8Keceli et al. (2015) [42]Stent, n = 1662.5 ± 1.8037.5 ± 24.0NA5.6 ± 10.3Medicinal plant extract + stent, n = 1744.1 ± 1.5818.8 ± 16.1NA0Kızıltoprak and Uslu (2020) [44]Coe pack, n = 12NA33.67 ± 20.99NA33.33 ± 18.42AFG + Coe pack, n = 12NA16.08 ± 16.37NA11.67 ± 15.34i-PRF + Coe pack, n = 12NA27.92 ± 14.38NA32.42 ± 16.27Lafzi et al. (2019) [45]Diode laser (808 nm, 50mW, 15 J/cm2, 30 s), n = 67NANA1Spontaneous Healing, n = 621NANA0Lavu et al. (2022)Diode laser (660 nm, 50mw, 17.5 J/cm2), n = 14NA12.14 ± 8.93NA21.4 ± 5.79Spontaneous Healing, n = 19NA32.11 ± 8.55NA22.11 ± 9.18Morshedzadeh et al. (2022) [50]Sham irradiation + stent, n = 827.8 ± 20.825.7 ± 25.031.4 ± 33.925 ± 30.3LLLT GaAlAs 940 nm, 5 J/cm + stent, n = 824.2 ± 17.425.0 ± 18.726.4 ± 31.027.1 ± 23.3Nabiyi et al. (2024) [51]Mucoadhesives containing 0.8% HA, n = 13NA13.1 ± 10.3NA7.7 ± 6.0Mucoadhesives containing 0.2%, n = 13NA26.2 ± 14.5NA16.9 ± 10.3Mucoadhesives only, n = 13NA21.5 ± 16.3NA8.5 ± 13.4Oliveira et al. (2023)Placebo get, n = 14NA34.0 ± 3.44NA27.0 ± 36.5Green tea extract and HA gel, n = 14NA29.7 ± 60.3NA33.2 ± 37.3Sutures only, n = 14NA13.0 ± 1.89NA15.0 ± 26.2Ozcan et al. (2017) [53]L-PRF (2700 rpm for 12 min) + cyanoacrylate adhesive, n = 4220.02.60.20Cyanoacrylate adhesive, n = 4248.519.08.80Palatal stent, n = 4161.032.219.83.2Ozcelik et al. (2016) [54]low-intensity laser therapy, n = 2651 ± 1142 ± 1330 ± 1222 ± 7Collagen sponge + suture, n = 2676 ± 973 ± 1162 ± 1143 ± 1Palombo et al. (2024) [55]Compressive suture + hemostatic sponge, n = 1619.8 ± 21.216.9 ± 23.712.1 ± 22.514.6 ± 24.5Sutureless approach, n = 1619.4 ± 20.512.6 ± 14.76.1 ± 8.67.0 ± 9.1Pekbağrıyanık et al. (2021)Stent, n = 1834.4 ± 35.010.0 ± 21.96.10 ± 10.93.3 ± 10.3NAPP + stent, n = 1827.3 ± 26.315.0 ± 18.97.20 ± 13.63.3 ± 7.7Samani et al. (2017) [59]PRP (400 rpm for 8 min), n = 10NANANA0Spontaneous Healing, n = 10NANANA13.0 ± 12.5Sankar et al. (2021) [60]Chitosan + stent, n = 10NANANA8.5Aloe vera + Chitosan + stent, n = 10NANANA8Sen et al. (2024) [62]A-PRF2.65 ± 0.772.23 ± 1,142.07 ± 1,231.80 ± 1,26L-PRF2.14 ± 1.181.92 ± 1,141.60 ± 1,441.10 ± 1,17Shanmugam et al., (2010) [63]Collagen Sponge, n = 16NANANA19.3 ± 10.3Coe-Pak, n = 16NANANA38.0 ± 1.42Sharma et al. (2019) [64]Collagen dressing, n = 10NANANA32 ± 1.814Autogenous PRF membrane, n = 10NANANA19 ± 1.101Soheilifar et al. (2015) [65]Coe-Pak, n = 1316.2 ± 12.4419.2 ± 9.96NANAPlacebo, n = 1331.9 ± 22.2817.9 ± 19.33NANASpin et al. (2021) [67]Latex membrane + acrylic plate and surgical cement, n = 10NA6.7 ± 9.07NANAAcrylic plate and surgical cement, n = 14NA11.57 ± 18.9NANATabari et al. (2023) [68]Modified Hawley retainer, n = 1037.5 ± 29.626.5 ± 19.5NA10 ± 19.2Modified Hawley retainer with 5% propolis oral ointment, n = 106.2 ± 11.87.5 ± 13.8NA1.3 ± 3.5Tasdemir et al. (2016) [69]Stent, n = 156428NANAOT + stent, n = 153712NANATavelli et al. (2018) [70]Cyanoacrylate adhesive + suture, n = 1017151412Spongostan + suture, n = 1013141312Periodontal dressing, n = 10171598Spongostan + Cyanoacrylate + suture, n = 103452Suture, n = 1028221615Yıldırım et al. (2017) [77]Periodontal dressing,n = 12NA64.2 ± 18.3NA45.0 ± 22.70.12% HA, n = 12NA16.7 ± 15.5NA12.5 ± 15.40.8% HA, n = 12NA19.2 ± 18.3NA8.3 ± 15.2Yılmaz et al. (2022) [78]No treatment, n = 13NANANA26.4 ± 23.1Cyanoacrylate, n = 14NANANA25.4 ± 34.5NA Not available, PRF Platelet rich fibrin, NRS Numerical Rating Scale, VRS Verbal Rating Scale, PBM Photobiomodulation, CTG Connective tissue graft, LLLT Low-level laser therapy, SCTG Subepithelial connective tissue graft, FGG Free gingival graft, T-PRF Titanium-prepared platelet-rich fibrin, HA Hyaluronic acid, AFG Autologous fibrin glue, i-PRF Injectable platelet-rich fibrin, DGG Deepitheliazed gingival graft, OT Ozone therapy, A-PRF Advanced platelet-rich fibrin, PHT Phenytoin formulation, HOCI Hypochlorous acid, MEBO Moist exposed burn ointment, EPO Erythropoietin, n-Emo nano-emodin, PDT Photodynamic therapy, VS Versus, NSAID Non-steroidal anti-inflammatory drug, L-PRF Leucocyte- and platelet-rich fibrin, NAPP Non-thermal atmospheric pressure plasma Pain reported in visual analogue scale (VAS) on Days 1, 3, 5 and 7 post-intervention at the palatal graft harvesting site NA Not available, PRF Platelet rich fibrin, NRS Numerical Rating Scale, VRS Verbal Rating Scale, PBM Photobiomodulation, CTG Connective tissue graft, LLLT Low-level laser therapy, SCTG Subepithelial connective tissue graft, FGG Free gingival graft, T-PRF Titanium-prepared platelet-rich fibrin, HA Hyaluronic acid, AFG Autologous fibrin glue, i-PRF Injectable platelet-rich fibrin, DGG Deepitheliazed gingival graft, OT Ozone therapy, A-PRF Advanced platelet-rich fibrin, PHT Phenytoin formulation, HOCI Hypochlorous acid, MEBO Moist exposed burn ointment, EPO Erythropoietin, n-Emo nano-emodin, PDT Photodynamic therapy, VS Versus, NSAID Non-steroidal anti-inflammatory drug, L-PRF Leucocyte- and platelet-rich fibrin, NAPP Non-thermal atmospheric pressure plasma Pain perception after palatal graft harvesting A total of 39 studies reported pain scores using the VAS in terms of mean and standard deviation; these are presented in Table 2. An additional eight studies reported VAS pain scores using median values: Alasfar et al. [13], Alpan et al. [17], Ehab et al. [26], Gatti et al. [32], Hassan et al. [34], Juber et al.[39], Khalil et al.[43], and Sousa et al. [66]. Among all studies, Day 7 was the most frequently reported time point, with pain scores recorded by 34 studies. All intervention groups showed improved pain scores compared to the control groups. The VAS scores across different postoperative days and treatment modalities reflect varying degrees of pain relief during the healing period. Pain typically peaked on Day 3, corresponding with the acute inflammatory phase following surgery. The highest pain score on Day 3 is reported by Ozcelik et al., of 73± 11 in the collagen sponge combined with sutures group, and Yildirim et al., of 64.2 ± 18.3 in patients using periodontal dressing on the palatal donor site [54, 77]. In contrast, the lowest pain score was reported by Isler et al. [38] of a score of 0 in patients using PRF combined with sutures and Essix retainer combined with sutures. By Day 7, a substantial reduction in pain was observed across all treatment groups, reflecting the typical progression of postoperative healing. PRF-based therapies consistently recorded the lowest pain scores, with PRF combined with sutures continuing to show no reported pain [38]. Other interventions also reporting no pain on Day 7 included the medicinal plant extract combined with a stent [42], the spontaneous healing group [45], the L-PRF and cyanoacrylate groups [53], and the PRP group [59]. In contrast, the highest VAS score on Day 7 of 75.2 ± 12.5 was observed in the cyanoacrylate group reported by Karimi et al., followed by a score of 68.0 ± 8.4 in the periodontal pack combined with stent group by Eldien et al. [27, 41]. Postoperative analgesic consumption In this review, 43 studies reported the prescription of postoperative analgesics (see Appendix 2). The duration of analgesic consumption monitoring ranged from the immediate postoperative hours, as reported by Tavelli et al. [71], to a maximum of 21 days in the study by Tabari et al. [68]. However, 16 studies did not specify the duration of monitoring. The most commonly prescribed analgesic was ibuprofen 400 to 600 mg in 13 studies, followed by paracetamol/acetaminophen 500 to 1000 mg in 7 studies, sodium dipyrone 500 mg (n = 4), unspecified non-steroidal anti-inflammatory drugs (NSAIDs) (n = 2), ketoprofen (n = 1), diclofenac potassium 50 mg (n = 1), and ketoprofen lysine salt 150 mg (n = 1). Analgesic consumption was reported either by the number of tablets or pills taken or by total dosage in milligrams. Notably, 18 of the 43 studies that reported analgesic use did not specify the type of analgesic prescribed. The evaluation of postoperative analgesic intake across various interventions highlights notable differences, with certain treatment modalities demonstrating a clear reduction in analgesic use. Bahammam et al., [18] and Heidari et al., [35] reported that the PRF combined with suture and low-level laser therapy groups required fewer analgesics compared to the control groups, suggesting that these treatments are effective in managing postoperative pain. In contrast, conventional treatments such as gelatin sponge and suture were associated with higher analgesic consumption. Femminella et al. demonstrated that the gelatin sponge combined with suture group consumed significantly more analgesics than the PRF combined with suture group, highlighting the superior pain-relieving properties of PRF [30]. Conversely, treatments involving stents or ozone therapy generally led to higher analgesic use. For instance, Tavelli et al. and Taşdemir et al. found that patients treated with stents required more analgesics than those receiving alternative treatments [69, 70]. Postoperative discomfort, morbidities, and measurement methods Postoperative discomfort and morbidity were assessed using several parameters, including: (i) Oral Health-Related Quality of Life (OHIP-14); (ii) postoperative bleeding; (iii) changes in diet or feeding habits; (iv) burning sensation at the donor site; (v) altered sensation at the donor site; (vi) sensation loss; (vii) postoperative stress; (viii) chewing ability; and (ix) speaking ability (see Appendix 3). Eight studies utilized the OHIP-14 questionnaire at various time intervals [25, 38, 39, 48, 49, 62, 69, 78]. Changes in diet or feeding habits were reported in five studies [16, 30, 36, 37, 75]. Burning sensation at the donor site, assessed using the VAS, was reported by ten studies [16, 17, 33, 36, 37, 63, 68, 73, 74, 77]. Postoperative bleeding was reported in 28 studies, using a variety of assessment methods. These included spontaneous bleeding within the first 24 h postoperatively, with no further spontaneous bleeding typically observed beyond Day 3 [21]. Other measures encompassed classifications such as immediate versus delayed bleeding, simple binary self-reports ("yes/no"), and more detailed tools like the VAS, reflecting a wide range of monitoring approaches. Most studies documented bleeding events primarily within the first 7 days, although some extended follow-up assessments to 14 days or up to 5 weeks. Notably, several studies emphasised individual variability in bleeding patterns, with marked differences in patient recovery trajectories. Palatal wound dressings All studies included in this review reported postoperative outcomes related to the use of various palatal wound dressings. A wide range of interventions, including single and combined approaches, were employed across the studies. The distribution of these intervention categories is summarised in Table 3. The most frequently applied intervention overall belonged to the physical barrier category (n = 32), which included cyanoacrylate, stents, periodontal packs, and membranes, used either alone or in combination with other interventions. Among the control groups, the most common approach was no treatment or suturing alone (n = 28), followed by the use of physical barriers (n = 24). Table 3Grouping of Intervention(s) and Control(s) According to the Type of InterventionAuthor, Year of PublicationIntervention(s)Physical BarriersChemical/MedicationHaemostatic AgentLasers/Photobiomodulation/OzoneControl(s)Physical BarrierSuture Only/No TreatmentChemical/MedicationHaemostatic AgentLasers/Photobiomodulation/Ozone1Al-Hezaimi et al., 2011 [11]Ketorolac Tromethamine (KT) Adhesive Film✓✓Adhesive Film/Suture✓✓2Al-Sherbini et al., 2024 [24]Ozone Therapy✓Periodontal Dressing✓3Alasfar et al., 2023 [13]10% Curcuma Longa Extract Gel (Turmeric Gel)✓Periodontal Dressing✓4Alasqah et al., 2022 [14]Honey Based Dressing✓No Dressing✓5Alghriany et al., 2024 [15]Orange Peel Polymethoxy-Flavonoids✓Alvogyl/Placebo Dough✓✓6Alkaya et al., 2023 [16]Zinc-containing Surgical Stent✓✓Gelatin-Based Hemostatic Agent✓7Alpan et al., 2023 [27]Hyaluronic Acid Gel/HOCl Spray/Furbiprofen Spray✓No Treatment✓8Bahammam et al., 2018 [18]PRF✓Suture✓9Basma et al., 2022Collagen Plug with Cyanoacrylate/PRF✓✓Collagen Plug✓10Bitencourt et al., 2022 [20]Diode Laser✓Placebo/Suture✓11Castro-Gaspar et al., 2021 [21]Cyanoacrylate✓Suture✓12da Silva Neves et al., 2016 [22]Photobiomodulation✓Suture✓13Dharani et al., 2025Ozonated Oil + Stent✓✓Stent✓14Dias et al., 2015 [24]LLLT✓Sham✓15Doshi et al., 2021 [25]Topical Phenytoin + Stent✓✓Placebo + Stent✓16Ehab et al., 2020 [26]Alvogyl✓Gelatin Sponge✓17Eldien et al., 2022 [27]PRF + Stent/Ozonated Oil + Stent✓✓✓Periodontal Pack + Stent✓18Eltas et al., 2014 [28]Essix/Modified Essix/Modified Hawley✓Periodontal Dressing✓19Eltayeb et al., 2021 [29]Laser Harvested with Stent✓✓Laser Harvested✓20Femminella et al., 2016 [30]PRF✓Gelatin Sponge✓21Garapati et al., 2023 [31]Blue®M Gel + Absorbable Gelatin✓✓Gelatin Sponge✓22Gatti et al., 2023 [32]L-PRF✓Oxidized Regenerated Cellulose✓23Gulsever et al., 2025 [33]L-PRF✓Suture✓24Hassan et al., 2021 [34]Hyaluronic Acid Gel + Periodontal Pack✓✓MEBO + Periodontal Pack✓✓25Heidari et al., 2017 [35]Diode Laser✓Sham✓26Isler et al., 2018 [36]Flurbiprofen✓Placebo✓27Isler et al., 2018a [37]Laser/Ozone✓No Treatment✓28Isler et al., 2019 [38]PRF/Essix/Ozone/LLLT✓✓✓Suture✓29Juber et al., 2023Ozonated Sunflower Oil✓Non-Ozonated Sunflower Oil✓30Kadkhoda et al., 2020 [40]Human Amniotic Membrane✓✓Suture✓31Karimi et al., 2024 [41]Cyanoacrylate✓Suture✓32Keceli et al., 2015 [42]Medicinal Plant Extract + Stent✓✓Stent✓33Khalil et al., 2022 [43]Collagen Sponge + HA + Periodontal Dressing✓✓✓Collagen Sponge + Periodontal Dressing✓✓34Kiziltoprak et al., 2020AFG + Coe Pack/I-PRF + Coe Pack✓✓Coe Pack✓35Lafzi et al., 2019 [45]Diode Laser✓No Treatment✓36Madi et al., 2018 [46]Simvastatin/Simvastatin + Chitosan/Chitosan Gel✓Petroleum Gel✓37Meza-Mauricio et al., 2023 [47]Collagen Sponge + Resin✓✓Collagen Sponge✓38Miguel et al., 2020Electrotherapy + Suture✓Suture✓39Miguel et al., 2021 [49]Emdogain✓No Treatment✓40Morshedzadeh et al., 2022 [50]LLLT + Stent✓✓Stent✓41Nabiyi et al., 2024 [51]Mucoadhesive + HA✓✓Mucoadhesive✓42Oliveira et al., 2023Green Tea Extract + HA✓Suture/Placebo✓43Ozcan et al., 2017 [53]L-PRF + Cyanoacrylate/Cyanoacrylate✓✓Stent✓44Ozcelik et al., 2016 [54]Low Intensity Laser✓Collagen Sponge✓45Palombo et al., 2024 [55]Haemostatic Sponge✓No Treatment✓46Pataropongsanti et al., 2019PRF✓Oxidized Regenerated Cellulose✓47Pekbagriyanik et al., 2021Atmospheric pressure plasma✓Stent✓48Rossmann et al., 1999 [58]Oxidized Regenerated Cellulose✓Gelatin Sponge✓49Samani et al., 2017PRF✓No Treatment✓50Sankar et al., 2021 [60]Aloe Vera + Chitosan + Stent✓✓Chitosan + Stent✓✓51Scott et al., 2024PRF✓Oxidized Regenerated Cellulose✓52Sen et al., 2024PRF✓Collagen Spomge✓53Shanmugam et al., 2010 [63]Coe-Pak✓Collagen Sponge✓54Sharma et al., 2019 [64]PRF✓Collagen Dressing✓55Soheilifar et al., 2015 [65]Coe-Pak✓Placebo✓56Sousa et al., 2020A-PRF✓Gelatin sponge✓57Spin et al., 2021 [67]Latex Membrane + Acrylic Plate✓Acrylic Plate/Suture✓✓58Tabari et al., 2023 [68]Hawleys Retainer + Propolis Ointment✓✓Hawleys Retainer✓59Tasdemir et al., 2016 [69]Ozone Therapy✓Stent✓60Tavelli et al., 2018 [70]Cyanoacrylate/Spongiostan/Periodontal Dressing✓✓Suture✓61Tavelli et al., 2019 [71]Cyanoacrylate + Collagen Sponge✓✓Collagen Sponge✓62Tirone et al., 2021 [72]Bipolar Coagulator + Collagen Sheet✓✓Collagen Sheet✓63Ustaoglu et al., 2016 [73]T-PRF + Non-Eugenol Pack + Stent✓✓Non-eugenol Pack + Stent✓64Ustaoglu et al., 2017 [74]Laser + Stent✓✓Stent✓65Yadav et al., 2024 [75]Chitosan Dressing✓Suture✓66Yaghobee et al., 2018Erythropoitin Gel✓Placebo Gel✓67Yildirim et al., 2018Hyaluronic Acid + Periodontal Dressing✓✓Periodontal Dressing✓68Yilmaz et al., 2022Cyanoacrylate✓No Treatment✓Yussif et al., 2021 [79]Propylene Mesh✓Acrylic Stent✓ Grouping of Intervention(s) and Control(s) According to the Type of Intervention Among the test group interventions, 42 were classified as single category interventions, while 26 involved combinations from multiple categories. Of the single category interventions, laser based therapies such as diode laser, photobiomodulation, low level laser therapy, ozone therapy, and electrotherapy were the most frequently investigated, appearing in 11 studies [12, 20, 22, 24, 29, 35, 37, 45, 48, 54, 70]. Platelet rich fibrin (PRF/L PRF) was also commonly studied, reported in nine studies [18, 30, 32, 33, 56, 59, 61–63, 65, 67]. Discussion A core outcome set refers to a standardized, consensus-driven group of outcomes that should be measured and reported as a minimum in all clinical trials within a specific area of health or healthcare. As recommended by the Implant Dentistry Core Outcome Set and Measurement [80], these outcomes typically include life impact such as quality of life and overall satisfaction with treatment. The management of postoperative pain is particularly important, as it directly influences the evaluation of surgical efficacy and patient satisfaction. In palatal graft harvesting surgery, donor site pain typically peaks between the first and third postoperative days, corresponding to the acute inflammatory phase and gradually subsides to near baseline by Day 7. This pattern aligns with findings by Burkhardt and Lang [81], who identified the first three days as the peak pain period, followed by a decline as healing progresses. The reduction in pain is likely due to blood clot stabilisation and the onset of reepithelialisation. Consistent with studies by Burkhardt and Lang, Nobuto et al. [81] and Oliver et al. [82] pain and burning sensations tend to diminish during the second healing phase and resolve by the third, coinciding with complete surface epithelialisation. This trend was also observed in the present review, where pain markedly decreased by Day 7. Notably, PRF therapies were associated with significantly lower pain scores, sometimes eliminating pain entirely by Day 7, and were linked to reduced postoperative analgesic use compared to conventional approaches such as suturing or spontaneous healing. Nonetheless, inconsistencies in the reporting of analgesic type, dosage, and duration significantly limit the strength and comparability of findings across studies. Many studies lack sufficient detail regarding analgesic protocols or patient adherence, which undermines the reliability of postoperative pain assessments and complicates cross-study comparisons. Furthermore, the potential influence of analgesic use on pain intensity and other patient-reported outcome measures is rarely examined, leaving an important gap in the understanding of how analgesia may confound or modulate these outcomes. Beyond pain, this review identified several patient-reported outcome measures related to donor site morbidity, including bleeding, altered sensation, burning, and difficulties with daily activities such as eating, chewing, and speaking. Consistent with the findings of Leite et al. [5], these important outcomes were rarely assessed in detail. Only a small number of studies utilised validated instruments such as the OHIP-14 to evaluate oral health-related quality of life. Traditionally, dental research has emphasised clinician-reported outcomes such as treatment success, healing time, and complication rates which may not fully reflect the patient’s experience. PROMs provide valuable insights into how patients perceive and are affected by treatment, yet their implementation across studies remains inconsistent. A variety of dressing materials and mechanical protective appliances have been used to protect the palatal wound and reduce donor site morbidity. Most studies reported a reduction in postoperative discomfort and morbidity regardless of the dressing type used. Notably, PRF consistently showed strong effectiveness in reducing postoperative pain. Biologically active dressings like PRF and L-PRF appeared more effective in pain control and reducing analgesic use than conventional physical barriers. Meanwhile, laser-based therapies, including photobiomodulation and low-level laser therapy, also showed positive outcomes, although evidence was varied. In contrast, physical barriers such as cyanoacrylate, stents, and periodontal packs were more effective in managing early bleeding, with mixed results for pain relief. Several unique combinations of palatal wound dressings were reported in only one or two studies, including advanced platelet-rich fibrin (AFG) or injectable PRF (i-PRF) with COE-PAK™, hyaluronic acid with periodontal dressing, nonthermal atmospheric pressure plasma with acrylic stents, and other combinations involving medicinal plant extracts, ozone therapy, chitosan, aloe vera, and MEBO. While these approaches show potential, the limited number of studies evaluating each combination makes it difficult to draw definitive conclusions about their effectiveness. The wide variety of dressing types and intervention combinations also complicates efforts to identify the most effective single treatment. Notably, an attempt at a network meta-analysis of wound healing agents for palatal donor sites by Oliveira et al. [8] was only able to include six trials for pain outcomes on Days 1 and 3, and five trials for pain on Day 7, highlighting the challenges posed by heterogeneity and limited data availability across studies. In the present review, only 12 studies were judged to have a low risk of bias, with most studies rated as high risk or raising some concerns. The greatest sources of bias stemmed from inadequate outcome measurement and selective reporting. The overall methodological quality thus raises caution when interpreting the reported outcomes. Consistent use of validated scales, proper blinding, and detailed reporting of follow-up are essential to improving future research quality. A key limitation of this systematic review is the high degree of heterogeneity among the included studies, largely due to methodological and clinical differences in the interventions. Variations in study design, including follow-up duration, number of treatment arms, outcome measures, and the use of postoperative analgesics, complicated data comparison and limited the ability to draw definitive conclusions, necessitating a narrative synthesis rather than a quantitative meta-analysis. Although all employed FGG or DGG techniques, inconsistent protocols and outcome reporting led to substantial between-study heterogeneity. This was especially evident in the pooled analyses where I2 values exceeded 99 percent. In a network meta-analysis, Oliveira et al. [8] identified leukocyte platelet-rich fibrin (L-PRF) as the most effective intervention for reducing postoperative pain, promoting wound healing, and minimising complications following palatal soft tissue graft harvesting. However, the authors noted that the limited number of included studies may have compromised the reliability of treatment rankings. The certainty of evidence for pain outcomes was rated very low due to within-study bias, and substantial heterogeneity was observed across analyses—driven by differences in active agents, study designs, pain assessment tools, wound healing measures, and follow-up periods. In contrast, a more recent systematic review by Leite et al. [5], which included additional studies, was unable to conduct even pairwise comparisons due to the wide methodological variability. The present review, which incorporated 14 additional studies not included by Leite et al., adding 451 participants, also encountered high heterogeneity, which prevented the execution of a meta-analysis. Conclusion This review highlights the wide range of interventions used to manage pain and reduce morbidity at the palatal donor site, where all intervention groups showed improved pain scores compared to controls. The pain associated with graft harvesting varies significantly, with VAS scores ranging from 0 to 73 ± 11 on Day 3 and from 0 to 75.2 ± 12.5 on Day 7. Pain is typically most intense during the first three days postoperatively, with a noticeable reduction in severity after Day 3. In addition to pain, other postoperative complications such as burning sensations, altered sensitivity, and changes in feeding habits have been reported following palatal graft harvesting. To strengthen clinical recommendations, future high-quality randomised controlled trials are needed, using standardised outcome measures that include both clinician-assessed and patient-reported outcomes. The adoption of a core outcome set, particularly one that captures pain, morbidities, and quality of life, will support more consistent, patient-centred, and evidence-based care. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Acknowledgements The authors would like to thank Universiti Kebangsaan Malaysia for their support and funding (GGPM 2022-024), Surgical Solutions Sdn Bhd and GluStitch Inc. for the continuous support and invaluable contributions to this work. Authors’ contributions Conceptualization: NMNA, BB; Methodology: CWJ, NMNA, MR; Formal analysis: NMNA, BB, CWJ; Data Curation: MR, BB; Writing-original draft preparation: CWJ, NMNA; Writing-review and editing: BB, MR; Visualization: NMNA, BB; Supervision: NMNA, BB, MR; Project administration: NMNA; Funding acquisition: NMNA, BB, MR. Funding The authors received funding from the Universiti Kebangsaan Malaysia (GGPM 2022–024). Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.